checkAd

     123  0 Kommentare BioDelivery Sciences to Report First Quarter 2020 Financial Results on May 7, 2020

    RALEIGH, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

    Conference Call Dial-In & Webcast Information:

    Date:  Thursday, May 7, 2020
    Time: 4:30 PM Eastern Time
    Domestic: 800-289-0571
    International: 720-543-0206
    Conference ID: 6176462
    Webcast: http://public.viavid.com/index.php?id=139300

    About BioDelivery Sciences International, Inc.
    BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain, opioid dependence, and opioid-induced constipation.

    2020 BioDelivery Sciences International, Inc. All rights reserved.

    Contact:
    Tirth T. Patel
    Director of Investor Relations
    tpatel@bdsi.com
    (919) 582-0294




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    BioDelivery Sciences to Report First Quarter 2020 Financial Results on May 7, 2020 RALEIGH, N.C., April 28, 2020 (GLOBE NEWSWIRE) - BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced …